ex vivo culture circulating breast tumor cells individualized testing drug susceptibility 
circulating tumor cells ctcs present low concentrations peripheral blood patients solid tumors proposed isolation ex vivo culture characterization ctcs may provide opportunity noninvasively monitor changing patterns drug susceptibility individual patients tumors acquire new mutations proof-of-concept study established ctc cultures six patients estrogen receptor-positive breast cancer three five ctc lines tested tumorigenic mice genome sequencing ctc lines revealed preexisting mutations pik3ca gene newly acquired mutations estrogen receptor gene esr1 pik3ca gene fibroblast growth factor receptor gene fgfr2 among others drug sensitivity testing ctc lines multiple mutations revealed potential new therapeutic targets optimization ctc culture conditions strategy may help identify best therapies individual cancer patients course disease 
